Brown University receives $30 million for Alzheimer's research

Brown University receives $30 million for Alzheimer's research

Brown University has announced gifts totaling $30 million from donors who wish to remain anonymous for a center dedicated to the early detection and treatment of Alzheimer's disease and related dementias.

Established with gifts of $25 million and $5 million, the Center for Alzheimer's Disease Research will bring together scientists and physicians at Brown's Robert J. and Nancy D. Carney Institute for Brain Science and Division of Biology and Medicine, home to the Warren Alpert Medical School, to build on the university's existing strengths in Alzheimer's disease research, which range from the study of risk genes, cognition, and the biology of aging to the development of new therapeutics and care of patients with dementia. A portion of the $25 million lead gift will be used to seed multidisciplinary efforts that incentivize collaborative Alzheimer's research projects across the university and its affiliated hospital, while the $5 million gift will be used to recruit a full-time leader for the center.

The funding also will be used to establish a fully staffed fluid biomarker facility, enabling the center to bridge basic laboratory science and clinical patient-focused research, inform biological and brain science research through direct access to patient-derived biomarkers and genetic data, and expand an existing partnership with a translational research team from Lund University in Sweden.

"This is truly a transformative moment for Alzheimer's disease and dementia research at Brown," said Brown University president Christina H. Paxson. "We have a robust foundation in place, and by bringing aboard new scholars, investing in facilities, and creating the infrastructure to connect the incredible work already happening in our labs and clinical settings, our goal is to accelerate development toward novel treatments and cures in the fight against this devastating disorder."

"The aim of the new center is to convene that expertise at Brown," said Diane Lipscombe, who leads the Carney Institute and will serve as the initial director of the center. "Ultimately, our work will contribute to a more thorough understanding of the most fundamental mechanisms involved in neurodegeneration, which will enable earlier diagnosis as well as the creation of treatments that will not just slow degeneration but also prevent it."